Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

888 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.
Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Herzog TJ, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Tassoudji M, Navale L, Warner DJ, Oza AM. Monk BJ, et al. Among authors: vergote i. Lancet Oncol. 2014 Jul;15(8):799-808. doi: 10.1016/S1470-2045(14)70244-X. Epub 2014 Jun 17. Lancet Oncol. 2014. PMID: 24950985 Clinical Trial.
The role of interval debulking surgery in ovarian cancer.
van der Burg ME, Vergote I; Gynecological Cancer Group of the EORTC. van der Burg ME, et al. Among authors: vergote i. Curr Oncol Rep. 2003 Nov;5(6):473-81. doi: 10.1007/s11912-003-0008-8. Curr Oncol Rep. 2003. PMID: 14521806 Review.
A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study.
Hirte H, Vergote IB, Jeffrey JR, Grimshaw RN, Coppieters S, Schwartz B, Tu D, Sadura A, Brundage M, Seymour L. Hirte H, et al. Among authors: vergote ib. Gynecol Oncol. 2006 Aug;102(2):300-8. doi: 10.1016/j.ygyno.2005.12.020. Epub 2006 Jan 25. Gynecol Oncol. 2006. PMID: 16442153 Clinical Trial.
Ovarian cancer.
Colombo N, Van Gorp T, Parma G, Amant F, Gatta G, Sessa C, Vergote I. Colombo N, et al. Among authors: vergote i. Crit Rev Oncol Hematol. 2006 Nov;60(2):159-79. doi: 10.1016/j.critrevonc.2006.03.004. Epub 2006 Oct 2. Crit Rev Oncol Hematol. 2006. PMID: 17018256 Review.
Chemotherapy for recurrent cervical cancer.
Cadron I, Van Gorp T, Amant F, Leunen K, Neven P, Vergote I. Cadron I, et al. Among authors: vergote i. Gynecol Oncol. 2007 Oct;107(1 Suppl 1):S113-8. doi: 10.1016/j.ygyno.2007.07.004. Epub 2007 Sep 4. Gynecol Oncol. 2007. PMID: 17804044 Review.
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial.
Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, O'Reilly S, Verrill M, Smith I, Yarnold J, Coleman R, Earl H, Canney P, Twelves C, Poole C, Bloomfield D, Hopwood P, Johnston S, Dowsett M, Bartlett JM, Ellis I, Peckitt C, Hall E, Bliss JM; TACT Trial Management Group; TACT Trialists. Ellis P, et al. Lancet. 2009 May 16;373(9676):1681-92. doi: 10.1016/S0140-6736(09)60740-6. Lancet. 2009. PMID: 19447249 Free PMC article. Clinical Trial.
888 results